-
1Academic Journal
Συγγραφείς: M. I. Volkova, A. S. Olshanskaya, I. V. Tsimafeyeu, N. L. Vashakmadze, Yu. A. Khochenkova, E. Sh. Solomko, S. A. Ashuba, D. A. Khochenkov, V. B. Matveev, М. И. Волкова, А. С. Ольшанская, И. В. Тимофеев, Н. Л. Вашакмадзе, Ю. А. Хоченкова, Э. Ш. Соломко, С. А. Ашуба, Д. А. Хоченков, В. Б. Матвеев
Συνεισφορές: Исследование выполнено при поддержке Российского научного фонда (грант № 19-15-00442).
Πηγή: Cancer Urology; Том 16, № 1 (2020); 17-26 ; Онкоурология; Том 16, № 1 (2020); 17-26 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2020-16-1
Θεματικοί όροι: рецепторы фактора роста тромбоцитарного происхождения (PDGFR-α, PDGFR-β), tumor venous thrombosis, vascular endothelial growth factor (VEGF-A), fibroblast growth factor 2 (FGF-2), VEGFR-1, 2 receptors, FGFR-1, platelet-derived growth factor receptors (PDGFR-α, опухолевый венозный тромбоз, фактор роста эндотелия сосудов (VEGF-A), фактор роста фибробластов 2 (FGF2), рецепторы VEGFR-1
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1020/1148; Lawindy S.M., Kurian T., Kim T. et al. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int 2012;110(7):926–39. DOI:10.1111/j.1464-410X.2012.11174.x.; Wagner B., Patard J.J., Méjean A. et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol 2009;55(2):452–9. DOI:10.1016/j.eururo.2008.07.053.; Давыдов М.И., Матвеев В.Б., Волкова М.И. и др. Резекция нижней полой вены у больных раком почки с массивным опухолевым тромбозом. Онкоурология 2018;14(2):15–25. DOI:10.17650/1726-9776-2018-14-2-15-25.; Abel E.J., Thompson R.H., Margulis V. et al. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur Urol 2014;66(3):584–92. DOI:10.1016/j.eururo.2013.10.029.; Kirkali Z., Van Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol 2007;52(3):658–62. DOI:10.1016/j.eururo.2007.05.009.; Detre S., Saclani Jotti G., Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48(9):876–8. DOI:10.1136/jcp.48.9.876.; Tsimafeyeu I., Zolotareva T., Varlamov S. et al. Five-year survival of patients with metastatic renal cell carcinoma in the Russian Federation: results from the RENSUR5 registry. Clin Genitourin Cancer 2017;15(6):e1069–72. DOI:10.1016/j.clgc.2017.07.017.; Tsimafeyeu I., Demidov L., Ta H. et al. Fibroblast growth factor pathway in renal cell carcinoma. J Clin Oncol 2011;28(15_suppl):4621. DOI:10.1200/jco.2010.28.15_suppl.4621.; Porta C., Paglino C., Imarisio I. et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013;84(2):115–22. DOI:10.1159/000342099.; aule B., Bastien L., Deslandes E. et al. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 2010;5(5):e10715. DOI:10.1371/journal.pone.0010715.; Tsimafeyeu I., Zaveleva E., Stepanova E., Low W. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Invest New Drugs 2013;31(6):1436–43. DOI:10.1007/s10637-013-0017-x.; Tsimafeyeu I., Volkova M., Olshanskaia A. et al. Expression of receptor tyrosine kinases on peripheral blood mononuclear cells and tumor-infiltrating lymphocytes in patients with renal cell carcinoma and healthy donors. Oncology 2020. DOI:10.1159/000505373. Online first.; Horstmann M., Merseburger A.S., von der Heyde E. et al. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J Cancer Res Clin Oncol 2005;131(11):715–22. DOI:10.1007/s00432-005-0019-y.; Fujimoto K., Ichimori Y., Yamaguchi H. et al. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 1995; 86(2):182–6. DOI:10.1111/j.13497006.1995.tb03037.x.; Duensing S., Grosse J., Atzpodien J. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res 1995;15(5B):2331–3.; Rasmuson T., Grankvist K., Jacobsen J., Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 2001;37(17):2199–203. DOI:10.1016/s0959-8049(01)00290-8.; Slaton J.W., Inoue K., Perrotte P. et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;158(2):735–43. DOI:10.1016/S0002-9440(10)64016-3.; Kluger H.M., Siddiqui S.F., Angeletti C. et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest 2008;88(9):962–72. DOI:10.1038/labinvest.2008.65.; Lkhagvadorj S., Oh S.S., Lee M.R. et al. VEGFR-1 expression relates to fuhrman nuclear grade of clear cell renal cell carcinoma. J Lifestyle Med 2014;4(1):64–70. DOI:10.15280/jlm.2014.4.1.64.; Iacovelli R., De Tursi M., Mosillo C. et al. Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents. Anticancer Res 2018;38(5):3105–10. DOI:10.21873/anticanres.12569.; Ho T.H., Liu X.D., Huang Y. et al. The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer 2015;15:304. DOI:10.1186/s12885-015-1302-1.; https://oncourology.abvpress.ru/oncur/article/view/1020